Skip to main content
Publications
Kummar S, Shen L, Martinus van Tilburg C, Tan DSW, Doz F, McDermott RS, Zwaan CM, Keating KN, Chirila C, Norenberg R, Fellous MM, Brega N, Xu R, Laetsch TW, Drilon AE, Hong DS. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. Poster presented at the 2022 ASCO Annual Meeting; June 3, 2022. Chicago, IL. [abstract] Am J Clin Oncol. 2022 Jun; 40(16_suppl):6563. doi: 10.1200/JCO.2022.40.16_suppl.6563
Ko DT, Khan AM, Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007
Bjornsdottir E, Janson C, Lindberg E, Arnardottir ES, Benediktsdottir B, Garcia-Aymerich J, Carsin AE, Real FG, Toren K, Heinrich J, Nowak D, Sanchez-Ramos JL, Demoly P, Arenas SD, Navarro RC, Schlunssen V, Raherison C, Jarvis DL, Gislason T. Respiratory symptoms are more common among short sleepers independent of obesity. BMJ Open Respir Res. 2017 Aug 30;4(1):e000206. doi: 10.1136/bmjresp-2017-000206